Xiuning Le: Should Combinations Be the Standard for 1L EGFR NSCLC After MARIPOSA and FLAURA2?
Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on LinkedIn by KOL Pulse, adding:
“Now that both MARIPOSA and FLAURA2 demonstrated overall survival (OS) benefit over osimertinib monotherapy in 1L EGFR NSCLC patients.
Should we consider combinations as the standard treatments, and osimertinib monotherapy only as an option for very-low risk and frail EGFR patients?”
Quoting KOL Pulse’s post:
“FLAURA2 OS results were just announced by AstraZeneca for the treatment of patients with EGFRmut mNSCLC!
KOLs have been discussing the significance of these trial data for the past 3 years!
- Which patients should receive the various regimens: FLAURA, FLAURA2, or MARIPOSA by Johnson and Johnson
- What are the best treatment sequences after the 1L regimen?
- What are the impacts of toxicities on treatment?
- What is the role of ctDNA?
Follow this X article for a breakdown of key presentations at major Oncology meetings, including commentary by Lung Cancer Thought Leaders.
Slides from presentations by Drs. Pasi Jänne, Roy Herbst, Marina Chiara Garassino, Julia Rotow, David Planchard, Antonio Passaro, Jonathan Riess, Remon Jordi, Natalia Valdiviezo Lama, Xiuning Le.
Top Influencers sharing this content include Drs. Eric Singhi, Stephen Liu, Balazs Halmos, Benjamin Besse and Jennifer Marks.
Patient Advocate Jill Feldman also shared important data from these meetings
Read Article Here.”
More posts featuring KOL Pulse and Xiuning Le.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023